Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pedi

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pedi
(NASDAQ: ARQT) Delayed: 24.38 -0.21 (0.85%)
Previous Close $24.59    52 Week High $ 
Open $24.64    52 Week Low $ 
Day High $24.99    P/E N/A 
Day Low $24.25    EPS $ 
Volume 1,329,350       

(NASDAQ: ARQT) Delayed: 24.38 -0.21 (0.85%)
Previous Close $24.59    52 Week High $ 
Open $24.64    52 Week Low $ 
Day High $24.99    P/E N/A 
Day Low $24.25    EPS $ 
Volume 1,329,350